Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care

19. november 2026 opdateret af: Montefiore Medical Center

Evaluation of Quality Improvement Initiative to Improve GLP-1 and CGM Prescription Rates

This randomized quality improvement study will evaluate whether pop-up alerts in the electronic health record (EHR) increase prescribing of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and continuous glucose monitors (CGMs) for eligible patients with diabetes. The study will be conducted at nine Montefiore Medical Group primary care sites. Primary care providers will be randomly assigned to either receive the alerts or not receive them. The alerts will remind providers that a patient is eligible for a GLP-1 RA, a CGM, or both, and will help them choose the option covered by the patient's insurance. Providers in both groups will use their own clinical judgment in deciding whether to prescribe. The study will use information already recorded in patients' medical records.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Primary care providers (physicians, physician assistants and nurse practitioners) are randomized 1:1, stratified by site type (teaching vs. non-teaching), prior GLP-1 RA prescribing, and eligible-patient volume. Approximately 121 providers will be randomized. The patients they see who meet eligibility criteria during the study period are the enrolled participants and are reflected in the enrollment count. Residents and their patients are excluded. For providers in the intervention arm, the alert is an Our Practice Advisory (OPA) in Epic that fires during qualifying in-person or telehealth primary care visits. Patients eligible for both a GLP-1 RA and a CGM trigger a single combined alert; patients eligible for only one trigger only that portion of the alert. Intervention-arm providers also receive education on using the alert. Outcomes are analyzed at the patient level using only each patient's first qualifying visit. The analysis uses mixed-effects logistic regression with a random effect for provider.

Note: The Albert Einstein College of Medicine Institutional Review Board (IRB) determined this quality improvement project does not meet the definition of human subjects research. An IRB determination letter is on file with this registration.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

2989

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New York
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • Montefiore Medical Center
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Meet Klompas definition of diabetes
  • Has at least one primary care visit, in-person or telehealth, during the study period
  • Is covered by Medicare or Medicaid

Additional inclusion criteria for the GLP-1 portion of the OPA alert:

  • GLP-1 component: HbA1c ≥ 9 on most recent lab test in the past 12 months and a BMI ≥ 25) OR BMI ≥ 30, and no GLP-1 prescription in the past 12 months

Additional inclusion criteria for the CGM portion of the OPA alert:

  • CGM component: Insulin prescription in the past 12 months and no CGM prescription in the past 12 months

Exclusion Criteria:

  • Patients seen by residents during their first visit

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Our Practice Advisory (OPA) Alert

Education will be provided on the use of the alerts to PCPs in the intervention group. Providers will continue using clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Electronic Health Record (EHR) Our Practice Advisory, a pop-up electronic notification for clinical staff available at the time of a clinical encounter in the electronic medical record, recommending the insurance-preferred GLP-1 and/or a CGM, plus education for providers on using the alerts

Ingen indgriben: Usual Care (UC)

Providers continue usual care, with no alert. Providers will use clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication
Tidsramme: At the first qualifying primary care visit during the study period, up to 3 months

The percentage of patients meeting the GLP-1 RA alert eligibility criteria who are newly prescribed a GLP-1 RA covered by their insurance, as documented in the electronic health record. GLP-1 RAs not covered by the patient's insurance are not counted. Each patient's first qualifying visit during the study period is analyzed.

At the first qualifying primary care visit during the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed a CGM
Tidsramme: At the first qualifying primary care visit during the study period, up to 3 months

The percentage of patients meeting the CGM alert eligibility criteria who are newly prescribed a continuous glucose monitor (CGM), as documented in the electronic health record. Each patient's first qualifying visit during the study period is analyzed.

At the first qualifying primary care visit during the study period, up to 3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Provider Response to the OPA alert
Tidsramme: Throughout the study period, up to 3 months

For the OPA arm only, providers interaction with the OPA alert will be evaluated based on the percentage of time the OPA alert fired and was either: ignored, declined, and approved. The unit of analysis are patients. Each nominal categorical variable will be summarized.

Throughout the study period, up to 3 months
Reasons for Declining the OPA alert
Tidsramme: Throughout the study period, up to 3 months

Among alert firings declined by providers in the OPA Alert arm, the percentage for each decline reason selected in the electronic health record will be summarized. The reasons are: Defer to Next Visit; Patient Declines; Chart Review Only; Does Not Meet Criteria; Financial Limitations; Treatment Ineffective; Patient Can't Tolerate. The unit of analysis are patients.

Throughout the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication by Patient Characteristics
Tidsramme: Throughout the study period, up to 3 months

Primary outcome evaluated by patient Body Mass Index (BMI) category, HbA1c category, Insulin status, Age group, Sex, and Race/Ethnicity. The unit of analysis are patients.

Throughout the study period, up to 3 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Shivani Agarwal, MD, MPH, Montefiore Medical Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. oktober 2026

Primær færdiggørelse (Anslået)

1. marts 2027

Studieafslutning (Anslået)

1. marts 2027

Datoer for studieregistrering

Først indsendt

5. november 2026

Først indsendt, der opfyldte QC-kriterier

17. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026-793

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .